论文部分内容阅读
目的检测分析2011-2015年分离自河南省5家腹泻病监测哨点医院病人粪便中的516株志贺菌血清型别、毒力基因及耐药表型.方法收集腹泻病人粪便,SS平板37℃分离培养18~24 h,疑似菌落进行API20E系统生化鉴定;阳性菌株进行志贺菌血清分型(玻片凝集法);多重PCR检测4种毒力基因(SHET-1B/SHET-2/ial/ipa H)并进行12种抗生素的药敏试验(K-B法,CLSI2015)。结果 516株志贺菌分离自19 217份粪便,检出率2.7%;阳性病例男女比例1.4∶1(301/215),以低龄儿童和青少年为主;分离时间多集中于每年的6-10月,具有较典型的夏秋季特征。菌株分为福氏(335株)和宋内(181株)2个群共9个血清型;394株志贺菌携带4种毒力基因,1种组合型别,122株携带3种毒力基因,3种组合型别。516株志贺菌对12种抗生素具有不同的耐药率,多重耐药菌株(R>3)为511株(99.1%),耐9种以上抗生素的菌株呈逐年上升趋势。结论河南省自监测系统中分离的志贺菌以福氏(B群)和宋内(D群)血清群为主,包含多种血清型别;菌株携带有不同的毒力基因并存在较为严重的耐药和多重耐药问题。
Objective To detect and analyze the serotypes, virulence genes and drug resistance phenotypes of 516 Shigella isolates from five diarrhea sentinel hospitals in Henan Province during 2011-2015.Methods Collect feces of patients with diarrhea, SS plate 37 After incubation for 18-24 h, the suspected colonies were biochemically identified by API20E system. The positive strains were serotyped by slide agglutination (slide agglutination method). Four virulence genes (SHET-1B / SHET-2 / ial / ipa H) and drug susceptibility testing of 12 antibiotics (KB method, CLSI2015). Results A total of 516 Shigella isolates were isolated from 19 217 stool samples and the detection rate was 2.7%. The male-to-female ratio of positive cases was 1.4:1 (301/215), mainly young children and adolescents. The separation time was mostly concentrated in 6-10 Month, with the typical summer and autumn features. The strains were divided into 9 serotypes: 2 strains of Freund’s (335 strains) and Songne (181 strains); 394 strains of Shigella carrying 4 virulence genes, 1 of which were combined and 122 strains of 3 strains of virulence Gene, 3 kinds of combination type. 516 strains of Shigella have different rates of resistance to 12 antibiotics, 511 strains (99.1%) were multi-drug resistant strains (R> 3), and the strains resistant to more than 9 antibiotics showed an increasing trend year by year. Conclusion The Shigella isolated from self-monitoring system in Henan province are mainly serogroups of B (F) and S (D) and contain many serotypes. Drug resistance and multi-drug resistance issues.